Reformulating Injectable Amiodarone®: A Breakthrough in Cardiac Care with Captisol Technology

[Article Title]

Injectable amiodarone has been a critical treatment for life-threatening cardiac arrhythmias for decades. Despite its clinical importance, the formulation has long been plagued by significant challenges. Traditionally, the drug relies on solvents such as polysorbate 80 (PS80) and benzyl alcohol to maintain solubility. These agents, however, introduce serious safety and practical concerns, including toxicity, instability, and incompatibility with standard intravenous (IV) materials.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.